
Fabio Mangiacapra

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4073731/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Point-of-Care Measurement of Clopidogrel Responsiveness Predicts Clinical Outcome in Patients Undergoing Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2008, 52, 1128-1133.	2.8	340
2	Bleeding and stent thrombosis on P2Y ₁₂ -inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. European Heart Journal, 2015, 36, 1762-1771.	2.2	297
3	Fractional Flow Reserve for the Assessment of Nonculprit Coronary Artery Stenoses in Patients With Acute Myocardial Infarction. JACC: Cardiovascular Interventions, 2010, 3, 1274-1281.	2.9	281
4	Evolving concepts of angiogram: fractional flow reserve discordances in 4000 coronary stenoses. European Heart Journal, 2014, 35, 2831-2838.	2.2	259
5	Functional SYNTAX Score for Risk Assessment in Multivessel Coronary Artery Disease. Journal of the American College of Cardiology, 2011, 58, 1211-1218.	2.8	251
6	Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial. Lancet, The, 2018, 392, 835-848.	13.7	215
7	Acute Kidney Injury After Radial or Femoral Access for Invasive Acute Coronary Syndrome Management. Journal of the American College of Cardiology, 2017, 69, 2592-2603.	2.8	132
8	Translesional Pressure Gradients to Predict Blood Pressure Response After Renal Artery Stenting in Patients With Renovascular Hypertension. Circulation: Cardiovascular Interventions, 2010, 3, 537-542.	3.9	108
9	Outcome Comparison of 600- and 300-mg Loading Doses of Clopidogrel in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2011, 58, 1592-1599.	2.8	107
10	Long-Term Follow-Up After Fractional Flow Reserve–Guided Treatment Strategy in Patients With an Isolated Proximal Left Anterior Descending Coronary Artery Stenosis. JACC: Cardiovascular Interventions, 2011, 4, 1175-1182.	2.9	95
11	A Therapeutic Window for Platelet Reactivity for Patients Undergoing Elective Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2012, 5, 281-289.	2.9	82
12	Long-Term Clinical Outcome After Fractional Flow Reserve–Guided Percutaneous Coronary Revascularization in Patients With Small-Vessel Disease. Circulation: Cardiovascular Interventions, 2012, 5, 62-68.	3.9	78
13	Platelet function and long-term antiplatelet therapy in women: is there a gender-specificity? A †state-of-the-art' paper. European Heart Journal, 2014, 35, 2213-2223.	2.2	78
14	Comparison of Platelet Reactivity and Periprocedural Outcomes in Patients With Versus Without Diabetes Mellitus and Treated With Clopidogrel and Percutaneous Coronary Intervention. American Journal of Cardiology, 2010, 106, 619-623.	1.6	72
15	High Residual Platelet Reactivity After Clopidogrel. JACC: Cardiovascular Interventions, 2010, 3, 35-40.	2.9	65
16	Circadian variations of ischemic burden among patients with myocardial infarction undergoing primary percutaneous coronary intervention. American Heart Journal, 2012, 163, 208-213.	2.7	60
17	Comparison of 600 Versus 300-mg Clopidogrel Loading Dose in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Coronary Angioplasty. American Journal of Cardiology, 2010, 106, 1208-1211.	1.6	55
18	Point-of-Care Assessment of Platelet Reactivity After Clopidogrel to Predict Myonecrosis in Patients Undergoing Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2010, 3, 318-323.	2.9	54

#	Article	IF	CITATIONS
19	Intracoronary Enalaprilat to Reduce Microvascular Damage During Percutaneous Coronary Intervention (ProMicro) Study. Journal of the American College of Cardiology, 2013, 61, 615-621.	2.8	53
20	Long-term clinical outcome after fractional flow reserve– versus angio-guided percutaneous coronary intervention in patients with intermediate stenosis of coronary artery bypass grafts. American Heart Journal, 2013, 166, 110-118.	2.7	52
21	Effective Radiation Dose, Time, and Contrast Medium to Measure Fractional Flow Reserve. JACC: Cardiovascular Interventions, 2010, 3, 821-827.	2.9	41
22	Influence of rs5065 Atrial Natriuretic Peptide Gene Variant on Coronary Artery Disease. Journal of the American College of Cardiology, 2012, 59, 1763-1770.	2.8	40
23	Clopidogrel reloading in patients undergoing percutaneous coronary intervention on chronic clopidogrel therapy: results of the ARMYDA-4 RELOAD (Antiplatelet therapy for Reduction of) Tj ETQq1 1 0.78431	l 421 .g BT /O	væøock 10 T
24	Quantitative angiography and optical coherence tomography for the functional assessment of nonobstructive coronary stenoses: Comparison with fractional flow reserve. American Heart Journal, 2013, 166, 1010-1018.e1.	2.7	39
25	Relation of Endothelial Function to Residual Platelet Reactivity After Clopidogrel in Patients With Stable Angina Pectoris Undergoing Percutaneous Coronary Intervention. American Journal of Cardiology, 2010, 105, 333-338.	1.6	35
26	Periprocedural variations of platelet reactivity during elective percutaneous coronary intervention. Journal of Thrombosis and Haemostasis, 2012, 10, 2452-2461.	3.8	34
27	Contrast-Induced Nephropathy in Patients Undergoing Primary Percutaneous Coronary Intervention Without Acute Left Ventricular Ejection Fraction Impairment. American Journal of Cardiology, 2013, 111, 684-688.	1.6	34
28	Impact of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio on 5-Year Clinical Outcomes of Patients with Stable Coronary Artery Disease Undergoing Elective Percutaneous Coronary Intervention. Journal of Cardiovascular Translational Research, 2018, 11, 517-523.	2.4	34
29	Relationship between peripheral arterial reactive hyperemia and residual platelet reactivity after 600Âmg clopidogrel. Journal of Thrombosis and Thrombolysis, 2011, 32, 64-71.	2.1	33
30	Impact of Chronic Kidney Disease on Platelet Reactivity and Outcomes of Patients Receiving Clopidogrel and Undergoing Percutaneous Coronary Intervention. American Journal of Cardiology, 2014, 113, 1124-1129.	1.6	33
31	Clopidogrel discontinuation and platelet reactivity following coronary stenting. Journal of Thrombosis and Haemostasis, 2011, 9, 24-32.	3.8	32
32	Clopidogrel Versus Ticagrelor for Antiplatelet Maintenance in Diabetic Patients Treated With Percutaneous Coronary Intervention. Circulation, 2016, 134, 835-837.	1.6	32
33	Thrombus aspiration in primary percutaneous coronary intervention in highâ€risk patients with STâ€elevation myocardial infarction: A realâ€world registry. Catheterization and Cardiovascular Interventions, 2010, 76, 70-76.	1.7	30
34	ACEF and clinical SYNTAX score in the risk stratification of patients with heavily calcified coronary stenosis undergoing rotational atherectomy with stent implantation. Catheterization and Cardiovascular Interventions, 2014, 83, 1067-1073.	1.7	30
35	High value of midâ€regional proadrenomedullin in COVIDâ€19: A marker of widespread endothelial damage, disease severity, and mortality. Journal of Medical Virology, 2021, 93, 2820-2827.	5.0	29
36	Comparison of drug-eluting versus bare-metal stents after rotational atherectomy for the treatment of calcified coronary lesions. International Journal of Cardiology, 2012, 154, 373-376.	1.7	28

FABIO MANGIACAPRA

#	Article	IF	CITATIONS
37	In Stent Neo-Atherosclerosis: Pathophysiology, Clinical Implications, Prevention, and Therapeutic Approaches. Life, 2022, 12, 393.	2.4	27
38	Relationship of asymmetric dimethylarginine (ADMA) with extent and functional severity of coronary atherosclerosis. International Journal of Cardiology, 2016, 220, 629-633.	1.7	26
39	Understanding the heart-brain axis response in COVID-19 patients: A suggestive perspective for therapeutic development. Pharmacological Research, 2021, 168, 105581.	7.1	26
40	Correlation of Platelet Reactivity and C-Reactive Protein Levels to Occurrence of Peri-Procedural Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention (from the) Tj ETQq0 0 0 rgBT /	Over6lock (10215f 50 617
41	Heart Rate reduction by Wabradine for improvement of ENDothELial function in patients with coronary artery disease: the RIVENDEL study. Clinical Research in Cardiology, 2017, 106, 69-75.	3.3	25
42	Nitroso-Redox Balance and Modulation of Basal Myocardial Function: An Update from the Italian Society of Cardiovascular Research (SIRC). Current Drug Targets, 2015, 16, 895-903.	2.1	25
43	Long-term clinical outcome in patients with small vessel disease treated with drug-eluting versus bare-metal stenting. American Heart Journal, 2011, 162, 907-913.	2.7	24
44	von Willebrand Factor Inhibition Improves Endothelial Function in Patients with Stable Angina. Journal of Cardiovascular Translational Research, 2013, 6, 364-370.	2.4	20
45	Prognostic role of preprocedural glucose levels on short―and longâ€ŧerm outcome in patients undergoing percutaneous coronary revascularization. Catheterization and Cardiovascular Interventions, 2012, 80, 377-384.	1.7	19
46	Efficacy of Clopidogrel Reloading in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention During Chronic Clopidogrel Therapy (from the Antiplatelet) Tj ETQq0 0 0 rgl	3T /Qverlo	ck_10 Tf 50 3
46	American Journal of Cardiology, 2013, 112, 162-168.	1.0	19
47	Efficacy and Safety of Paclitaxel-Coated Balloon for the Treatment of In-Stent Restenosis in High-Risk Patients. American Journal of Cardiology, 2015, 116, 1690-1694.	1.6	19
48	From SYNTAX to FAME, a paradigm shift in revascularization strategies. Journal of Cardiovascular Medicine, 2011, 12, 538-542.	1.5	18
49	Platelet reactivity and coronary microvascular impairment after percutaneous revascularization in stable patients receiving clopidogrel or prasugrel. Atherosclerosis, 2018, 278, 23-28.	0.8	18
50	Thresholds for platelet reactivity to predict clinical events after coronary intervention are different in patients with and without diabetes mellitus. Platelets, 2014, 25, 348-356.	2.3	17
51	Effects of Prasugrel Versus Clopidogrel on Coronary Microvascular Function in Patients Undergoing Elective PCI. Journal of the American College of Cardiology, 2016, 68, 235-237.	2.8	17
52	Coronary microcirculation and peri-procedural myocardial injury during elective percutaneous coronary intervention. International Journal of Cardiology, 2020, 306, 42-46.	1.7	17
53	Invasive Assessment of Coronary Microvascular Function. Journal of Clinical Medicine, 2022, 11, 228.	2.4	17
54	High cholesterol levels are associated with coronary microvascular dysfunction. Journal of Cardiovascular Medicine, 2012, 13, 439-442.	1.5	16

FABIO MANGIACAPRA

#	Article	IF	CITATIONS
55	NT-proANP circulating level is a prognostic marker in stable ischemic heart disease. International Journal of Cardiology, 2012, 155, 311-312.	1.7	16
56	Clinical Implications of Platelet—Vessel Interaction. Journal of Cardiovascular Translational Research, 2013, 6, 310-315.	2.4	16
57	Glycemic Variability Assessed by Continuous Glucose Monitoring and Short-Term Outcome in Diabetic Patients Undergoing Percutaneous Coronary Intervention: An Observational Pilot Study. Journal of Diabetes Research, 2015, 2015, 1-11.	2.3	16
58	Fractional flow reserve (FFR) as a guide to treat coronary artery disease. Expert Review of Cardiovascular Therapy, 2018, 16, 465-477.	1.5	16
59	Influence of transradial versus transfemoral diagnostic heart catheterisation on peripheral vascular endothelial function. EuroIntervention, 2013, 8, 1252-1258.	3.2	16
60	Pressure–Diameter Relationship in Human Coronary Arteries. Circulation: Cardiovascular Interventions, 2012, 5, 791-796.	3.9	15
61	Safety and effectiveness of drug-eluting stents versus bare-metal stents in elderly patients with small coronary vessel disease. Archives of Cardiovascular Diseases, 2013, 106, 554-561.	1.6	14
62	High platelet reactivity and periprocedural myocardial infarction in patients undergoing percutaneous coronary intervention: A significant association beyond definitions. International Journal of Cardiology, 2015, 190, 124-125.	1.7	14
63	Transcriptional fingerprint of human whole blood at the site of coronary occlusion in acute myocardial infarction. EuroIntervention, 2011, 7, 458-466.	3.2	14
64	Synergistic effect of thrombus aspiration and abciximab in primary percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2013, 82, 604-611.	1.7	13
65	Relationship between time of day and periprocedural myocardial infarction after elective angioplasty. Chronobiology International, 2014, 31, 206-213.	2.0	13
66	Role of endothelial dysfunction in determining angina after percutaneous coronary intervention: Learning from pathophysiology to optimize treatment. Progress in Cardiovascular Diseases, 2020, 63, 233-242.	3.1	13
67	Lack of correlation between platelet reactivity and glycaemic control in type 2 diabetes mellitus patients treated with aspirin and clopidogrel. Journal of Thrombosis and Thrombolysis, 2011, 32, 54-58.	2.1	12
68	Relation of Neutrophil to Lymphocyte Ratio With Periprocedural Myocardial Damage in Patients Undergoing Elective Percutaneous Coronary Intervention. American Journal of Cardiology, 2016, 118, 980-984.	1.6	11
69	Impact of platelet reactivity on 5-year clinical outcomes following percutaneous coronary intervention: a landmark analysis. Journal of Thrombosis and Thrombolysis, 2018, 45, 496-503.	2.1	11
70	Association of Biomarkers of Lipid Modification with Functional and Morphological Indices of Coronary Stenosis Severity in Stable Coronary Artery Disease. Journal of Cardiovascular Translational Research, 2013, 6, 536-544.	2.4	10
71	Usefulness of Adding Pre-procedural Glycemia to the Mehran Score to Enhance Its Ability to Predict Contrast-induced Kidney Injury in Patients Undergoing Percutaneous Coronary Intervention Development and Validation of a Predictive Model. American Journal of Cardiology, 2021, 155, 16-22.	1.6	10
72	Endothelial dysfunction as predictor of angina recurrence after successful percutaneous coronary intervention using second generation drug eluting stents. European Journal of Preventive Cardiology, 2018, 25, 1360-1370.	1.8	9

#	Article	IF	CITATIONS
73	Incremental Value of Platelet Reactivity Over a Risk Score of Clinical and Procedural Variables in Predicting Bleeding After Percutaneous Coronary Intervention via the Femoral Approach. Circulation: Cardiovascular Interventions, 2015, 8, .	3.9	8
74	Prevalence Of familial hypercholeSTerolaemia (FH) in Italian Patients with coronary artERy disease: The POSTER study. Atherosclerosis, 2020, 308, 32-38.	0.8	8
75	Comparison Among Patients ≥75ÂYears Having Percutaneous Coronary Angioplasty Using Drug-Eluting Stents Versus Bare Metal Stents. American Journal of Cardiology, 2015, 115, 1179-1184.	1.6	7
76	The Pivotal Role of Invasive Functional Assessment in Patients With Myocardial Infarction With Non-Obstructive Coronary Arteries (MINOCA). Frontiers in Cardiovascular Medicine, 2021, 8, 781485.	2.4	7
77	Idiopathic sensorineural hearing loss is associated with endothelial dysfunction. IJC Heart and Vasculature, 2016, 12, 32-33.	1.1	6
78	Relation of Platelet Indexes to Platelet Reactivity and Periprocedural Myocardial Infarction in Patients Who Underwent Percutaneous Coronary Angioplasty. American Journal of Cardiology, 2018, 121, 1027-1031.	1.6	6
79	Impact of Mediterranean diet on metabolic and inflammatory status of patients with polyvascular atherosclerotic disease. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 117-124.	2.6	6
80	α _{2A} -Adrenergic Receptor Polymorphism Potentiates Platelet Reactivity in Patients With Stable Coronary Artery Disease Carrying the Cytochrome P450 2C19*2 Genetic Variant. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 1314-1319.	2.4	5
81	Thrombus aspiration in primary percutaneous coronary intervention: still a valid option with improved technique in selected patients!. Cardiovascular Diagnosis and Therapy, 2017, 7, S110-S114.	1.7	5
82	Relationship between peripheral arterial reactive hyperemia and the index of myocardial resistance in patients undergoing invasive coronary angiography. International Journal of Cardiology, 2021, 333, 8-13.	1.7	5
83	Residual platelet reactivity: predicting short- and long-term clinical outcome in patients undergoing percutaneous coronary revascularization. Biomarkers in Medicine, 2010, 4, 421-434.	1.4	4
84	Antiplatelet effect of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: an analysis of the ARMYDA-6 MI (Antiplatelet therapy for Reduction of MYocardial Damage during) Tj ETQq0 0 0 rgBT /Overlocl	₹ 10 ⁷ Tf 50	292 Td (Angi
85	Glycaemic Control in Patients Undergoing Percutaneous Coronary Intervention: What Is the Role for the Novel Antidiabetic Agents? A Comprehensive Review of Basic Science and Clinical Data. International Journal of Molecular Sciences, 2022, 23, 7261.	4.1	4
86	Individual Variability of Response to Antiplatelet Therapy is an Important Determinant of Adverse Clinical Outcome. High Blood Pressure and Cardiovascular Prevention, 2010, 17, 121-130.	2.2	3
87	Optimizing Revascularization Strategies in Coronary Artery Disease for Optimal Benefit to Patients. Clinical Pharmacology and Therapeutics, 2011, 90, 630-633.	4.7	3
88	Impact of Tourniquet Use on Systemic Inflammatory Parameters, Functional Physical Recovery, and Cardiovascular Outcomes of Patients Undergoing Knee Arthroplasty: A Case-Control Study. Journal of Knee Surgery, 2020, 33, 762-767.	1.6	3
89	Interaction Between Diabetes Mellitus and Platelet Reactivity in Determining Long-Term Outcomes Following Percutaneous Coronary Intervention. Journal of Cardiovascular Translational Research, 2020, 13, 668-675.	2.4	3
90	Non-INvasive Functional and Anatomic vascular evaluation for the prediction of coronary artery disease: The NINFA study. International Journal of Cardiology, 2021, 322, 16-22.	1.7	3

Fabio Mangiacapra

#	Article	IF	CITATIONS
91	Current management and prognosis of patients with recurrent myocardial infarction. Reviews in Cardiovascular Medicine, 2021, 22, 731.	1.4	3
92	Ranolazine Improves Glycemic Variability and Endothelial Function in Patients with Diabetes and Chronic Coronary Syndromes: Results from an Experimental Study. Journal of Diabetes Research, 2021, 2021, 1-9.	2.3	3
93	Prediction of 5-Year Mortality in Patients with Chronic Coronary Syndrome Treated with Elective Percutaneous Coronary Intervention: Role of the ACEF Score. Journal of Cardiovascular Translational Research, 2021, 14, 1125-1130.	2.4	2
94	Impact of Chronic Kidney Disease and Platelet Reactivity on Clinical Outcomes Following Percutaneous Coronary Intervention. Journal of Cardiovascular Translational Research, 2021, 14, 1085-1092.	2.4	2
95	Platelet reactivity and clinical outcomes following percutaneous coronary intervention in complex higher-risk patients. Journal of Cardiovascular Medicine, 2022, 23, 135-140.	1.5	2
96	EXCEL and NOBLE: stents or surgery for left main stem stenosis?. EuroIntervention, 2017, 13, e604-e608.	3.2	2
97	REabsorbable vs. DUrable Polymer Drug-Eluting Stents in All-Comer PatiEnts: the REDUCE registry. Coronary Artery Disease, 2021, 32, 281-287.	0.7	2
98	Correlation between serum uric acid levels and residual platelet reactivity in patients undergoing PCI. Nutrition, Metabolism and Cardiovascular Diseases, 2017, 27, 470-471.	2.6	1
99	Rational and design of the INtentional COronary revascularization versus conservative therapy in patients undergOing successful peripheRAI arTEry revascularization due to critical limb ischemia trial (INCORPORATE trial). American Heart Journal, 2019, 214, 107-112.	2.7	1
100	Microvascular impairment associated with percutaneous coronary revascularization: The quest for protective microcirculatory strategies. International Journal of Cardiology, 2020, 308, 9.	1.7	1
101	P2Y12 inhibition in STEMI: early, strong or both?. EuroIntervention, 2018, 14, 25-27.	3.2	1
102	Prevalence and clinical impact of high platelet reactivity in patients with chronic kidney disease treated with percutaneous coronary intervention: An updated systematic review and metaâ€analysis. Catheterization and Cardiovascular Interventions, 2022, 99, 1086-1094.	1.7	1
103	Prediction of type 4a myocardial infarction with the angiography-derived hemodynamic (ADDED) index. Heart and Vessels, 2022, 37, 1471-1477.	1.2	1
104	Association Between Platelet Reactivity and Long-Term Bleeding Complications After Percutaneous Coronary Intervention According to Diabetes Status. American Journal of Cardiology, 2022, 171, 49-54.	1.6	1
105	Platelet Reactivity and Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2012, 60, 378-380.	2.8	0
106	TCT-56 Incremental value of platelet reactivity over a risk score of clinical and procedural variables in predicting bleeding events after percutaneous coronary intervention. Journal of the American College of Cardiology, 2012, 60, B17.	2.8	0
107	Stent thrombosis and platelet reactivity. Cor Et Vasa, 2013, 55, e151-e157.	0.1	0
108	Letter by Mangiacapra and Barbato Regarding Article, "Effects of Endothelial Dysfunction on Residual Platelet Aggregability After Dual Antiplatelet Therapy With Aspirin and Clopidogrel in Patients With Stable Coronary Artery Disease― Circulation: Cardiovascular Interventions, 2013, 6, e65.	3.9	0

FABIO MANGIACAPRA

#	Article	IF	CITATIONS
109	Platelet reactivity in patients carrying the e-NOS G894T polymorphism after a loading dose of aspirin plus clopidogrel. Thrombosis Research, 2017, 151, 72-73.	1.7	Ο
110	Endothelial dysfunction in patients with spontaneous coronary artery dissection: another brick in the failing coronary wall?. International Journal of Cardiology, 2020, 316, 52-53.	1.7	0
111	To treat or not to treat intermediate coronary lesions: Are we asking the question wrong?. International Journal of Cardiology, 2021, 338, 37-38.	1.7	0
112	Choosing the optimal antiplatelet therapy in atherosclerotic disease. Cardiovascular Diagnosis and Therapy, 2018, 8, 566-567.	1.7	0
113	730 Prediction of type 4a myocardial infarction with the angiography-derived haemodynamic (added) index. European Heart Journal Supplements, 2021, 23, .	0.1	Ο
114	Circadian variations of platelet reactivity on clopidogrel in patients treated with elective percutaneous coronary intervention. Journal of Thrombosis and Thrombolysis, 2022, , 1.	2.1	0